Yuying Han , Libao Xie , Mengqi Yuan , Yuteng Ma , Huimin Sun , Yuan Sun , Yongfeng Li , Hua-Ji Qiu 

Vet Microbiol. 2020 Aug;247:108741. doi: 10.1016/j.vetmic.2020.108741. Epub 2020 May 28.

Abstract

Classical swine fever (CSF) is a highly contagious and economically damaging disease. Classical swine fever virus (CSFV) lapinized vaccine C-strain against CSF worldwide lacks the capacity for the serological differentiation between infected and vaccinated animals (DIVA). To develop a marker C-strain complying with the DIVA principle, we generated and evaluated mutants rHCLV-E2F117A, rHCLV-E2G119A, and rHCLV-E2P122A, which harbor the single amino acid mutation at 117F, 119G or 122P of the monoclonal antibody HQ06-recognized epitope on the E2 glycoprotein in rabbits and pigs. Viral intravenous administration demonstrated that all the mutants retain the phenotype of C-strain in rabbits, including fever response induction and replication in the spleen. Notably, the HQ06-recognized epitope did not react with the antibodies induced by rHCLV-E2P122A in rabbits, in contrast with C-strain and other two mutants. Intramuscular administration of rHCLV-E2P122A in pigs induced anti-CSFV neutralizing antibodies but not antibodies against the HQ06-recognized epitope at 28 days post-inoculation. Collectively, our data demonstrate that rHCLV-E2P122A is a promising marker vaccine candidate against CSF.

Keywords: C-strain; Classical swine fever virus; Epitope; Marker vaccine.

Copyright © 2020 Elsevier B.V. All rights reserved.